Dr Reddys Laboratories Ltd Share Price
(DRREDDY)
₹1144.2
as on 04:01PM, 28 Mar 2025
Dr Reddy's Laboratories Performance
Day's Low
Day's High
₹1,140.75Day's Price Range₹1,159.2552 Week's Low
52 Week's High
₹1,092.4552-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | + 4.09 % |
| 3 Month Return | -15.59 % |
| 1 Year Return | -5.63 % |
| Market Stats | |
| Previous Close | ₹1,162.20 |
| Open | ₹1,159.25 |
| Volume | 27.63L |
| Upper Circuit | ₹1,278.40 |
| Lower Circuit | ₹1,046.00 |
| Market Cap | ₹96,980.40Cr |
Dr Reddy's Laboratories Fundamentals
P/E Ratio
18.02
PEG Ratio
11.05
Market Cap
₹96,980.40 Cr
P/B Ratio
4.22
EPS
66.882
Dividend Yield
0.65
Sector
Pharmaceuticals
ROE
19.42
Mutual Fund Holdings of Dr Reddy's Laboratories
Dr Reddy's Laboratories Analyst Rating
based on 38 analysts
36.84%
Buy
26.32%
Hold
36.84%
Sell
Based on 38 analysts offering long term price targets for Dr Reddy's Laboratories. An average target of ₹1334.61
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Share analysis
Dr Reddy's Laboratories price forecast by 38 analysts
Upside of14.83%
High
₹1723
Target
₹1334.61
Low
₹961
Dr Reddy's Laboratories target price ₹1334.61, a slight upside of 14.83% compared to current price of ₹1144.2. According to 38 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:24.73%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Dr Reddys Laboratories Ltd
Dr Reddys Partners with Bio-Thera for Biosimilars - 26 Mar, 2025
Dr Reddys Laboratories has entered into commercialization and licensing agreements with Bio-Thera Solutions for two proposed biosimilars, BAT2206 and BAT2506, targeting Southeast Asian markets and gaining exclusive rights in Colombia.Dr Reddys Schedules Meeting, Completes Facility Sale - 24 Mar, 2025
Dr Reddys Laboratories has scheduled a board meeting for May 9 to discuss financial results and dividends. Additionally, its subsidiary has finalized the sale of its Louisiana manufacturing facility.Dr Reddys Sells Louisiana Subsidiary - 23 Mar, 2025
Dr Reddys Laboratories has finalized the sale of its wholly owned subsidiary, Dr. Reddys Laboratories Louisiana LLC, including its manufacturing facility in Shreveport, Louisiana.Dr. Reddys Advances Biosimilar Development and Share Buying - 18 Mar, 2025
Dr. Reddys Laboratories and Alvotech received FDA acceptance for AVT03, a biosimilar to Prolia® and Xgeva®. They also signed a License Agreement for its development. Additionally, the company reported significant net buying of shares.Dr. Reddy's Issues Recall for Mislabeled Drug - 13 Mar, 2025
Dr. Reddy's Laboratories is recalling a batch of Levetiracetam Sodium Chloride Injection in the US due to mislabeling, which could lead to serious adverse effects. The recall affects a product distributed nationwide, with no reported adverse events yet.IPA Proposes Zero Tariff for US Pharma Imports - 07 Mar, 2025
The Indian Pharmaceutical Alliance has recommended to the government to eliminate tariffs on pharma imports from the US, which could benefit major companies like Dr Reddy's Laboratories.Dr Reddy's Laboratories Focuses on Global Capability Centers - 06 Mar, 2025
Phani Mitra B, Global CIO & CDO at Dr Reddy's Laboratories, outlined a vision for developing Global Capability Centers in India, emphasizing efficiency, differentiated capabilities, and integration as key success factors.Dr. Reddy's Sells ANDA Portfolio to Senores Pharma - 05 Mar, 2025
Dr. Reddy's Laboratories has entered an agreement to sell a portfolio of 14 Abbreviated New Drug Applications to Senores Pharmaceuticals. Current stock price is Rs 1,122, with downside risks noted.Dr. Reddy's Laboratories Targets Growth with New Developments - 03 Mar, 2025
Dr. Reddy's Laboratories is trading at a PE ratio of 17.4, below its 10-year median. Motilal Oswal sets a target price of Rs 1,330, indicating an 18.5% upside. The company is expanding its pipeline in North America and emerging markets, with potential developments in semaglutide and plans to file a biosimilar application by December 2025.Dr Reddy's Faces Challenges Amid US Tariff Concerns - 28 Feb, 2025
Dr Reddy's Laboratories discusses manageable impacts of potential US tariffs. Concerns about rising drug prices for US patients were echoed by industry leaders. The company remains focused on branded markets and oncology investments.Dr. Reddy's Reports Growth and Regulatory Approval - 27 Feb, 2025
Dr. Reddy's Laboratories announced a turnover increase for FY24 and received an Establishment Inspection Report from USFDA for its Hyderabad facility, with a profit rise in Q3 FY25.Go Digit Acquires Stake in Dr Reddy's Laboratories - 26 Feb, 2025
Go Digit General Insurance has purchased a 0.32% stake in Dr Reddy's Laboratories for ₹30.06 crore. The company reported revenue of ₹8,358 crore and a net profit of ₹1,403 crore for the December quarter.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 4 quarters, 7.31K Cr → 8.53K Cr (in ₹), with an average increase of 5.0% per quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, DRREDDY stock has moved up by 4.1%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.25K Cr → 1.41K Cr (in ₹), with an average increase of 11.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.86% to 11.14% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 9.97% to 10.22% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Dec 2024 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 27.53% to 26.85% in Dec 2024 quarter
Dr Reddy's Laboratories News
India Braces for US Tariffs: Stocks to Watch Ahead of April 2
Kranti Bathini, Director of Equity strategy at WealthMills Securities is confident that this is unlikely to be disrupted.28 Mar, 2025 10:24 AMDr. Reddy's Secures Exclusive Rights for Two Major Biosimilar Drugs in SE Asia
Dr. Reddy's will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, Vietnam. In addition, Dr. Reddys will also receive the exclusive commercial rights to BAT2206 in Colombia.27 Mar, 2025 09:17 PMDr Reddy's Partners with Bio-Thera for Biosimilars in Southeast Asia
Dr Reddys Labs on Wednesday said its subsidiary, Dr Reddys Labs SA, has entered into commercialisation and licencing agreements with Chinas Bio-Thera Solutions for biosimilars of two of Janssens human monoclonal antibodies (mABs) – Stelara (Ustekinumab) and Simponi (Golimumab) – for the South East Asian markets. While Bio-Theras BAT2206 is a proposed biosimilar of Stelara, BAT2506 is a proposed biosimilar of Simponi developed by Bio-Thera, a commercial-stage biopharmaceutical company that is developing a pipeline of innovative therapies and biosimilars. As part of the agreement, Bio-Thera will develop, manufacture and supply BAT2206 and BAT2506, while Dr Reddys will be responsible for seeking regulatory approvals and commercialise these two biosimilars in licensed territories in Southeast Asia that include Cambodia, Indonesia, Malaysia, Philippines, Thailand and Vietnam. Hyderabad-based Dr Reddys said it will also get exclusive commercial rights to market BAT2206 in Colombia as part of the deal.26 Mar, 2025 09:27 PMDr Reddy's Laboratories Financials
Dr Reddy's Laboratories Index Inclusions
Dr Reddy's Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | 0.00 | |
| Foreign Institutions | 26.85% | ||
| Mutual Funds | 11.14% | 2.57 | |
| Retail Investors | 10.22% | 2.49 | |
| Others | 25.15% | 0.64 |
Dr Reddy's Laboratories Key Indicators
Dr Reddy's Laboratories Valuation
Dr Reddy's Laboratories in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (18.02x)
March 27, 2025
Industry (53.19x)
March 27, 2025
Highest (53.88x)
December 18, 2020
Dr Reddy's Laboratories Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit jumped 2.38% since last year same period to ₹1,413.70Cr in the Q3 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.58% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 6.99%.
Read More about Dividends
Dr Reddy's Laboratories Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
Dr Reddy's Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹96,980.40 Cr | 18.81% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,55,900.41 Cr | 42.02% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,419.57 Cr | 45.98% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹41,486.73 Cr | 5.08% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹26,440.93 Cr | -2.36% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Revenue: ₹8,358.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,404.20Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddy's Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Dr Reddys Laboratories Ltd
What is Dr Reddys Laboratories Ltd price today?
Dr Reddys Laboratories Ltd share price today stands at ₹1144.2, Open: ₹1159.25, Previous Close: ₹1162.2, High: ₹1159.25, Low: ₹1140.75, 52 Week High: ₹1421.49, 52 Week Low: ₹1092.45.
How to Buy Dr Reddys Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Dr Reddys Laboratories Ltd shares
What are today's traded volumes of Dr Reddys Laboratories Ltd?
Today's traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 27.63L.
What is today's market capitalisation of Dr Reddys Laboratories Ltd?
Today's market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹96980.4Cr.
What is the 52 Week High and Low Range of Dr Reddys Laboratories Ltd?
How much percentage Dr Reddys Laboratories Ltd is down from its 52 Week High?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1144.2. It is down -19.51% from its 52 Week High price of ₹1421.49
How much percentage Dr Reddys Laboratories Ltd is up from its 52 Week low?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1144.2. It is up 4.74% from its 52 Week Low price of ₹1092.45